FAILED
首站-论文投稿智能助手
典型文献
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
文献摘要:
Background::The cancer burden in the United States of America (USA) has decreased gradually. However, China is experiencing a transition in its cancer profiles, with greater incidence of cancers that were previously more common in the USA. This study compared the latest cancer profiles, trends, and determinants between China and USA.Methods::This was a comparative study using open-source data. Cancer cases and deaths in 2022 were calculated using cancer estimates from GLOBOCAN 2020 and population estimates from the United Nations. Trends in cancer incidence and mortality rates in the USA used data from the Surveillance, Epidemiology, and End Results program and National Center for Health Statistics. Chinese data were obtained from cancer registry reports. Data from the Global Burden of Disease 2019 and a decomposition method were used to express cancer deaths as the product of four determinant factors.Results::In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. The most common cancers are lung cancer in China and breast cancer in the USA, and lung cancer is the leading cause of cancer death in both. Age-standardized incidence and mortality rates for lung cancer and colorectal cancer in the USA have decreased significantly recently, but rates of liver cancer have increased slightly. Rates of stomach, liver, and esophageal cancer decreased gradually in China, but rates have increased for colorectal cancer in the whole population, prostate cancer in men, and other seven cancer types in women. Increases in adult population size and population aging were major determinants for incremental cancer deaths, and case-fatality rates contributed to reduced cancer deaths in both countries.Conclusions::The decreasing cancer burden in liver, stomach, and esophagus, and increasing burden in lung, colorectum, breast, and prostate, mean that cancer profiles in China and the USA are converging. Population aging is a growing determinant of incremental cancer burden. Progress in cancer prevention and care in the USA, and measures to actively respond to population aging, may help China to reduce the cancer burden.
文献关键词:
Cancer;Incidence;Mortality;Trends;Aging;China;USA
作者姓名:
Xia Changfa;Dong Xuesi;Li He;Cao Maomao;Sun Dianqin;He Siyi;Yang Fan;Yan Xinxin;Zhang Shaoli;Li Ni;Chen Wanqing
作者机构:
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
引用格式:
[1]Xia Changfa;Dong Xuesi;Li He;Cao Maomao;Sun Dianqin;He Siyi;Yang Fan;Yan Xinxin;Zhang Shaoli;Li Ni;Chen Wanqing-.Cancer statistics in China and United States, 2022: profiles, trends, and determinants)[J].中华医学杂志(英文版),2022(05):584-590
A类:
colorectum
B类:
Cancer,statistics,China,United,States,profiles,trends,determinants,Background,burden,America,USA,has,decreased,gradually,However,experiencing,transition,its,greater,incidence,cancers,that,were,previously,more,common,This,study,compared,latest,between,Methods,was,comparative,using,open,source,data,cases,deaths,calculated,estimates,from,GLOBOCAN,population,Nations,Trends,mortality,rates,used,Surveillance,Epidemiology,End,Results,program,National,Center,Health,Statistics,Chinese,obtained,registry,reports,Data,Global,Burden,Disease,decomposition,method,express,product,four,factors,there,will,approximately,new,respectively,most,lung,breast,leading,cause,both,Age,standardized,colorectal,have,significantly,recently,liver,increased,slightly,Rates,stomach,esophageal,whole,prostate,other,seven,types,women,Increases,adult,size,aging,major,incremental,fatality,contributed,reduced,countries,Conclusions,decreasing,esophagus,increasing,mean,converging,Population,growing,Progress,prevention,care,measures,actively,respond,may,help,Incidence,Mortality,Aging
AB值:
0.459975
相似文献
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
Colorectal cancer burden,trends and risk factors in China:A review and comparison with the United States
Qianru Li;Hongliang Wu;Maomao Cao;He Li;Siyi He;Fan Yang;Xinxin Yan;Shaoli Zhang;Yi Teng;Changfa Xia;Ji Peng;Wanqing Chen-Office of Cancer Screening,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement,Beijing 100021,China;Department of Anesthesiology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Cancer Prevention and Control,Shenzhen Center for Chronic Disease Control,Shenzhen 518020,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。